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Bleeding from portal hypertensive gastropathy
(PHG) has been estimated to account for upto 30%
of all upper gastrointestinal haemorrhage in patients
with cirrhosis and portal hypertension. Although
portal hypertension seems to be an essential pre-
requisite, the precise mechanisms responsible for
the development of PHG are unknown. The aim of
this study was to examine the role of injection scle-
rotherapy of oesophageal varices in the development
of PHG. Gastric emptying was studied using a
radionuclide test meal with the emptying character-
istics of a slow liquid in 57 patients with cirrhosis
and/or portal hypertension (median age 53 yrs), of
whom 34 had received injection sclerotherapy for
their oesophageal varices and 20 normal healthy
volunteers (median age 42 yrs). As vagal damage is
associated with more rapid emptying of liquids,
despite hold up of solids, this technique might be
expected to demonstrate such damage if gastric
emptying was accelerated. The results indicated that
there was no difference in the rate of gastric
emptying between normal healthy volunteers and
portal hypertensive patients. However, patients who
had received injection sclerotherapy emptied their
stomachs faster than those who had not (p<0.05).
Furthermore, the speed of gastric emptying corre-
lated directly with the number of injections (r= 0.41;
p=0.02) and the volume of sclerosant injected
(r= 0.39; p 0.03). These observations suggest that
injection sclerotherapy for oesophageal varices
results in disturbances of gastric emptying that
may contribute to the pathogenesis of portal hyper-
tensive gastropathy.
Keywords: Portal hypertensive gastropathy, gastric empty-
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INTRODUCTION
Bleeding from the portal hypertensive gastric
mucosa has been estimated to account for up to
30% of upper gastrointestinal haemorrhage in
patients with cirrhosis and portal hypertension
[1-5]. Although variously described as "hae-
morrhagic gastritis" [6], "acute gastric erosions"
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[7], "acute mucosal lesions" [8], "alcoholic
gastritis" etc. [29] the term portal hypertensive
gastropathy (PHG) is currently accepted to
describe the gastric mucosal lesions responsible
for this condition [10]. The precise mechanisms
responsible for PHG are incompletely under-
stood but portal hypertension is considered to be
an essential prerequisite [11-13]. Injection scle-
rotherapy has been reported to exacerbate portal
hypertensive gastropathy, [5-14, 15], although
the mechanisms involved are unknown. One
possible explanation for the deleterious effect of
injection sclerotherapy on PHG is the gastric
mucosal congestion which results from the
obliteration of lower oesophageal veins. How-
ever, this is likely to arise only if blood flow in
the varices is cephalad which is not always the
case [16, 17]. A further possibility is that
extravasation of sclerosant into the mediastinum
can result in vagal damage producing a delay in
the rate of gastric emptying. Such a delay in
gastric emptying may prolong the exposure of
already susceptible gastric mucosa of portal
hypertensive patients to the deleterious effects
of acid and pepsin and exacerbate PHG. Since
this possibility has not been hitherto examined,
the aim of the present study was to investigate
gastric emptying in patients who had received
varying courses of elective sclerotherapy and
differing amounts of sclerosant to obliterate their
varices.
SUBJECTS AND METHODS
Subjects
The study was performed in 57 patients (33
males and 24 females, median age 53 years), of
whom 50 had cirrhosis of the liver (alcoholic 32,
primary biliary cirrhosis 7, cryptogenic 5, others
6) and 7 with extrahepatic portal hypertension
and 20 normal healthy volunteers (male 14,
female 6, median age 42 years). Clinical details
on each patient, including the number of
previous sclerotherapies and the total volume
of sclerosant (ethanolamine oleate) injected,
were obtained from the hospital case notes. All
patients has undergone extensive hepatic inves-
tigations prior to the study, to establish the
aetiology of the liver disease, and the extent of
hepatic dysfunction. The aetiology of cirrhosis
was confirmed by liver biopsy in all patients.
Patients with extra-hepatic pathology had overt
evidence of portal hypertension including oeso-
phageal varices and or/ascites. None of the
patients had active peptic ulceration at the time
of study. Patients with severe cardiac, renal, and
pulmonary disease were excluded from the
study. Also excluded from the study were those
patients admitted for an acute variceal bleed,
severe ascites or severe clotting disorders and
non-variceal upper gastrointestinal bleeding. No
patient had undergone any gastric surgery.
Ethical approval was obtained from the Hospital
Ethical Committee. All the studies were con-
ducted after obtaining written informed consent
from all patients and volunteers, and ARSAC
approval to carry out radionuclide gastric
emptying studies.
Methods
Gastric Emptying Studies
All gastric emptying studies were carried out at
least one week following sclerotherapy and after
a 12h fast. Drugs that could influence gastric
motility were discontinued 48h prior to the
study. The rate of gastric emptying (GE) was
measured using a semi-solid meal [18] which
99 rn consisted of 10MBq of Tc-labelled bran
incorporated into porridge made from Ready-
Brek(R) and milk, two cheese sandwiches and a
cup of tea. The total volume of the meal was
510 ml, the weight 430 g and the calorific content
2.7 MJ. Each patient sat at 45 on a chair in front
of a large field of view gamma camera interfaced
to a digital computer, and acquisition of the data
was commenced at the beginning of the meal atPORTAL HYPERTENSIVE GASTROPATHY? 143
a rate one frame per minute. At the end of the
study, a composite image of the stomach was
obtained by summing the first ten frames of the
study. Two regions of interest (ROIs) were then
drawn on this image, defining the stomach
content and a background area. The counts in
each ROI on each frame of the study were then
obtained and a gastric emptying curve and
background curve produced. A background
corrected gastric emptying curve was derived.
by subtracting the individual background curve
value multiplied by the quotient of the number
of the cells in the gastric ROI and the number of
the cells in the background ROI from each value
of the gastric curve at each time interval. After
correcting for radioactive decay the gastric
empltying curve was finally displayed as a
percentage emptying curve, by dividing each
point of the curve by the maximum curve
value and then multiplying by 100. The time
taken for 50% GE (t 1/2) was used to express the
results.
STATISTICAL ANALYSIS
The area under the curve method was used for
analysis of GE. Differences between groups were
assessed by Mann-Whitney U or Kruskal-Wallis
H tests. The Spearman’s rank correlation coeffi-
cient was used to determine the association
between two variables. A ’p’ value of less than
0.05 was considered to be statistically significant.
RESULTS
Of the 57 patients studies, 44 had oesophageal
varices and 34 had received previous injection
sclerotherapy. The oesophageal varices had been
completely obliterated in 17 of these patients for
periods varying from 5 months to 7 years. The
number of sclerotherapies ranged from 1-17
(median 5) and the volume of sclerosant injected
from 5.5-86.5 ml (median 39 ml).
As shown in Figure 1, there was no significant
difference in the rate of GE between normal
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FIGURE Gastric emptying (t 1/2) of patients who had not received injection sclerotherpy (Non-inj), patients who had
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subjects (median 57 min., range 30-67 min.) and
patients who had not received injection sclero-
therapy (median 56 min., range 39-77 min.).
However, the rate of GE was significantly faster
in patients who had received previous injection
sclerotherapy for their oesophageal varices
compared to cirrhotic patients without oesopha-
geal varices and those with varices who had
received no sclerotherapy (median 46 min.,
range 23-76 min.). There was no difference in
the rate of GE between 17 patients with
completely obliterated varices (median 56 min.,
range 39-77 min.) and 17 others who had
received injection sclerotherapy but whose
varices were still patent (median 58 min., range
40-77 min.). However, the rate of GE correlated
significantly with the number (r 0.41;
p=<0.02) of previous sclerotherapy sessions
(Fig. 2) and the volume (r=- 0.39; p= < 0.03) of
sclerosant injected (Fig. 3).
DISCUSSION
It has been suggested that injection sclerother-
apy may play a role in the gastric mucosal
changes characteristic of PHG. Thus, in a small
uncontrolled series, McCormack et al. [5] ob-
served that PHG appeared for the first time after
successful obliteration of oesophageal varices by
sclerotherapy in 6 patients. However in another
5 patients, variceal eradication appeared to
coincide with disappearance of gastric lesions.
Sarin et al. [14] reported a high incidence of a
"mosaic like" pattern in the gastric mucosa of
patients following obliteration of their varices.
However, in that study, the incidence of PHG
prior to sclerotherapy was unknown, making it
impossible to ascertain the role of sclerosis in the
pathogenesis of the condition. D’Amico et al. [15]
observed that PHG tended to appear and never
to improve during a course of elective sclero-
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FIGURE 2 Correlation between gastric emptying (t 1/2) and the number of injection sclerotherapy sessions in patients with
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Correlation between gastric emptying (t 1/2) and the volume of scerosant injected in patients with esophageal
therapy, and in some patients occurred before
obliteration of the varices was achieved. Further-
more, these investigators also noted that the
number of overt haemorrhages from PHG was
remarkably increased after sclerotherapy. Kot-
zampassi et al. [19] reported that a highly
statistically significant number of patients devel-
oped PHG within 6 months after variceal
obliteration by sclerotherapy. Thus 18 out of 20
of their patients with normal gastric mucosa
prior to sclerotherapy developed moderate to
severe PHG after obliteration of their varices.
Furthermore 17 patients with mild gastropathy
developed moderate to severe PHG after sclero-
therapy.
Although the foregoing discussion indicates
an increase in the incidence of PHG after
injection sclerotherapy, the precise mechanism
remains unclear. One possible explanation is
that the gastric mucosal changes occur as a
result of alterations in local haemodynamics
following obliteration of the lower oesophageal
veins. Previous studies [16, 17] have shown that
the blood flow patterns in oesophageal varices
may not always be cephalad but can often be
towards the stomach offering an explanation for
the observation that some patients develop
PHG, whereas others do not.
Another possible explanation for the effects of
injection sclerotherapy on the development of
PHG is that extravasation of sclerosant into the
mediastinum results in a "chemical vagotomy"
which may be responsible for the alterations in
oesophageal motility reported after multiple
sessions of sclerotherapy [20, 21]. If this is
indeed the case, then a "chemical vagotomy"
should also delay gastric emptying of solids
which may exacerbate PHG, by exposing the
already susceptible gastric mucosa of portal
hypertensive patients to the deleterious effects
of acid and pepsin. There is some indirect
evidence to support this hypothesis. Thus in146 K.K. BALAN et al.
portal hypertensive rats, restraint results in the
development of gastric lesions and haemor-
rhage, which are abolished by truncal vagotomy
and pyloroplasty [22]. Pyloroplasty was intro-
duced in man to accelerate gastric emptying in
patients who developed stasis after truncal
vagotomy alone. Therefore a chemical vagotomy
without any drainage procedure should pro-
mote gastric stasis and exacerbate PHG by
exposing the gastric mucosa to the deleterious
effects of gastric contents for longer periods.
The results of present study suggest that there
is no difference in the rate of GE of a semi-solid
meal between normal subjects and patients who
had received injection sclerotherapy. These
observations conflict with those of Bonvoisin
et al. [23] who demonstrated a delay in GE of
both solids and liquids, the latter more pro-
nounced, in 9 patients with alcoholic cirrhosis
who had undergone sclerotherapy, compared to
8 normal healthy controls. Stein et al. [24] has
studied gastric motility in two patients before
and after injection sclerotherapy. However, the
number of subjects included in these two studies
are too small to properly assess the significance
of the results. Nevertheless, the conflicting
findings between the previous study by Bonvoi-
sin et al. [23] and our own cannot be explained
by the difference in the test meal used in the two
studies, since the former had demonstrated a
delay in GE of both solid and liquid meals
whereas we observed a faster rate of GE using a
semi-solid meal. However, if vagal damage
resulted in abnormalities of GE after injection
sclerotherapy, solid meals should empty slower
and liquids or semi-solids faster than in normal
controls. Therefore, the observations of Bonvoi-
sin et al. [23] cannot be explained in terms of
vagal damage per se. In the present study, not
only the rate of GE was significantly faster in
patients who had received injection sclerother-
apy compared to those who had not, although
there was considerable overlap between the two
groups. These observations would suggest that
in patients who received a small number of
sclerotherapy sessions and hence a small volume
of sclerosant, there is minimal damage and
therefore little or no damage in the rate of GE.
However, as the number of courses of injection
sclerotherapy and the volume of the sclerosant
administered increases the rate of GE increases
as the vagal damage becomes more pronounced.
This suggestion is supported by the positive
correlations between the rate of GE and both the
number of injections as well as the volume of
sclerosant injected. These observations would
suggest that injection sclerotherapy plays an
independent role in causing the faster GE of a
semi-solid meal in portal hypertensive patients.
The most likely explanation for this increased
rate of GE after injection sclerotherapy is the
effect of the procedure on vagal function. The
proximity of the anterior and posterior trunks of
vagus nerve to the lower oesophagus probably
makes them vulnerable to the deleterious effects
of any sclerosant that extravasates into the
mediastinum. The test meal used in the present
study has the emptying characteristics of a slow
liquid. Therefore, it would appear that the
effects of sclerotherapy on the rate of GE is
analogous to that which occurs after highly
selective vagotomy whereby liquids empty
faster as a result of loss of receptive relaxation
of the proximal stomach [21, 26]. Furthermore,
gastric emptying of liquids has also been noted
to be faster after truncal vagotomy [27] which
affects gastric antral motility, resulting in a delay
in emptying of solids. Thus the degree of
damage to the vagus can theoretically dictate
the nature of any resulting GE abnormality. A
delay in gastric emptying can expose the already
vulnerable gastric mucosa of portal hypertensive
patients to the deleterious effects of endogenous
"aggressive" substances like acid and pepsin
and thereby cause aggravation of or the devel-
opment of PHG.
Previous studies have demonstrated distur-
bance in autonomic nervous function in cirrhosis
regardless of its aetiology [28, 29]. If this is
indeed the case, gastric motor function can bePORTAL HYPERTENSIVE GASTROPATHY? 147
affected in a way analogous to different vago-
tomies, depending on the degree of vagal
denervation. Autonomic function, however,
was not formally assessed in our study popula-
tion. In a recent study by Isobe et al. [30] in
cirrhotics, although there was evidence of
impaired cardiac autonomic function, there
was a poor correlation between this and gastric
emptying. Thus, it would seem unlikely that a
disturbance in autonomic function was respon-
sible for the alterations in the rate of GE
observed in the present study.
In summary, the results of this study suggest
that disturbances of GE may occur after injection
sclerotherapy particularly in those patients who
have received a large number of courses of
sclerosis and hence volume of sclerosant.
Furthermore, these disturbance in GE may
contribute to the development of PHG, since
the patterns of abnormal GE observed after scle-
rotherapy particularly in those patients who had
received a large number of sclerotherapies and
hence a large volume of sclerosant appear to be
consistent with vagal damage. However, there
was considerable overlap between the rate of GE
in patients who had or had not received injection
sclerotherapy. Further larger studies are there-
fore required between patients who have under-
gone a larger number of courses of injection
sclerotherapy and those who have received less
or no sclerosis before the clinical significance of
the findings in this study can be confirmed.
Furthermore, data from pH-metry and manome-
try may also be required for precise evaluation
of "chemical vagotomy".
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COMMENTARY
Though it has been appreciated for some time
that gastrointestinal symptoms are common in
patients with chronic liver disease, until recently
few studies had documented the true frequency
of any specific gastrointestinal symptoms are
common in patients with chronic liver disease,
until recently few studies had documented the
true frequency of any specific gastrointestinal
symptom or symptom complex in liver disease
[31]. Furthermore, little is known of the patho-
physiology of these symptoms and their rela-
tionship to gut function. Over the past several
years, a number of investigator have attempted
to evaluate some aspects of gastrointestinal
function in patients with portal hypertension
and chronic liver disease. Particular attention
has been focused on gastric motor dysfunction.
Stimulated, perhaps, by the description of
gastric mucosal changes related to portal hyper-
tension [32] and of related effects on acid
secretion and gastric mucosal defense [33], a
number of reports have documented alterations
in gastric emptying in patients with liver disease
and portal hypertension [33-36]. The precise
nature of this effect, however, remains contro-
versial, with some studies demonstrating an
acceleration and others a delay in gastric
emptying. Many factors, including inter-species
differences, the severity of underlying liver
disease and the relative predominance of effects
on regional gastric function might explain these
discrepancies. Thus, an effect on the gastric
fundus could result in an impairment in
receptive relaxation and accelerated emptying,
while altered antral contractibility would delay
emptying. One could also speculate that reduc-
tions in fundic compliance could lead, through
the generation of high post-prandial intragastric
pressures, to the precipitation of transient lower
esophageal sphincter relaxation, and, thereby,
gastroesophageal reflux [37].
In this issue of the journal, Balan and his
colleagues address another variable which
might influence gastric emptying, in patients
with portal hypertension who are treated with
endoscopic sclerotherapy. Their provocative
hypothesis suggests that sclerotherapy might
result in a chemical vagotomy, and thereby exert
typical vagotomy effects on liquid and solid
emptying from the stomach.
Esophageal dysfunction following injection
sclerotherapy is, indeed, an important clinical
phenomenon [38]. For the most part, however,
esophageal dysfunction following sclerotherapy
is related to mucosal ulceration and stricturePORTAL HYPERTENSIVE GASTROPATHY? 149
formation. Sclerotherapy has also been asso-
ciated with changes in esophageal motor func-
tion, which include impaired peristaltic
amplitude and an increased incidence of abnor-
mal contractile waves in the lower esophagus
[39]. This study, however, is the first to examine
sclerotherapy effects on the stomach. While
failing to observe any difference in gastric
emptying rate between their portal hypertensive
patients as an entire group and healthy volun-
teers, Balan and colleagues report that patients
who received injection sclerotherapy demon-
strated more rapid emptying of a semi-solid
meal than those who had not. Furthermore,
emptying rate appeared to correlate with both
the number of sclerotherapy injections and the
total volume of sclerosant injected.
These findings suggest that prior sclerother-
apy may be yet another variable which could
affect gastric emptying in patients with portal
hypertension and liver disease, and contribute to
the variability that has been noted among
various studies. While interpretation of their
study is limited by a number of factors including
a relative paucity of information on control
subjects, a failure to separately evaluate solid
and liquid emptying and a lack of correlation
with symptoms or time from sclerotherapy, this
study suggests, at the very least, that a history of
prior sclerotherapy should be factored into an
evaluation of gastrointestinal motor function in
this patient group. Based on prior experience,
one would expect vagotomy to result in an
acceleration of liquid emptying and a retarda-
tion of solid emptying; why emptying of a semi-
solid meal should have been accelerated in this
study remains unclear. Further direct studies of
vagal function are required and will need to
factor in the known prevalence of autonomic
dysfunction in patients with chronic liver dis-
ease, per se [40].
Given the high prevalence of gastrointestinal
symptoms suggestive of gastric motor dysfunc-
tion among patients with liver disease and
portal hypertension, further prospective studies
of gastric function in this patient group are
warranted, in doing so, one must obviously take
into account the many factors which may
contribute to gastric motor dysfunction in this
population [41].
Eamonn M. M. Quigley MD, FRCP
Layton F. Rikkers MD
Departments of Internal Medicine and Surgery
University of Nebraska Medical Center
600 So 42nd St.
Omaha, Nebraska 68198-2000
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The precise mechanisms responsible for the
development of portal hypertensive gastropathy
(PHG) are unknown.150 K.K. BALAN et al.
The aim of this study was to examine the role
of injection sclerotherapy of oesophageal varices
in the development of PHG.
Gastric emptying was studied using a radio
nuclide test meal with the emptying charac-
teristics of a slow liquid in 57 patients with
cirrhosis (of whom 34 had received injection
sclerotherapy for their oesophageal varices) and
20 normal healthy volunteers.
The speed of gastric emptying is correlated
directly with the number of injections and the
volume of sclerosant injected.
The injection sclerotherapy has been reported
to exacerbate the PHG (5-14-15):
one possible explanation is the getting worse
of the gastric mucosal congestion after the
obliteration of lower oesophageal veins.
a further possibility is the extravasation of
sclerosant into the mediastinum with a vagal
damage and a delay in the rate of gastric
emptying.
Moreover the extension of the exposure of
gastric mucosa to the acid and pepsin may
exacerbate PHG.
A very large number of patients with oeso-
phageal varices would have to be followed to
elucidate the effects of injection sclerotherapy,
on vagal function.
A more precise evaluation of "Chemical
vagotomy" requires ph-metry and manometry.
.I hope that other studies bring into the rate of
gastric emptying before and after injection
sclerotherapy with a multicentre controlled
trial.
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